Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron boss “delighted” with long-term stroke data

“These positive long term results are highly encouraging, indicating that the CTX therapy has the potential to produce meaningful and sustained improvements in disability as well as motor function in disabled stroke patients”
stroke drugs
There are currently no therapeutic interventions available to improve motor function and quality of life for stroke patients

ReNeuron Group Plc (LON:RENE) was in demand early on Tuesday after the cell-based therapeutics specialist delivered another encouraging update from its phase II clinical study treating stroke patients with its CTX stem cells.

Last December, ReNeuron reported that seven-out-20 patients taking part in the PISCES II trial saw a discernible improvement in their disability.

READ: Encouraging short-term data from PISCES II stroke study

The AIM-quoted group said on Tuesday that the positive response rates reported at three months after treatment were sustained at 12 months after treatment, with seven people still showing a “clinically relevant improvement”.

The PISCES II trial also showed that the CTX treatment was well-tolerated both in the short and longer-term.

"We are delighted that the long term follow-up data from the PISCES II clinical trial has shown the potential of our CTX cell therapy candidate to permanently improve function in patients living with chronic consequences following stroke,” said ReNeuron chief executive Olav Hellebø.

“Further, the study we plan to commence early in 2018 will allow critical placebo-controlled data with CTX in stroke disability to be available earlier than originally planned.”

IND application to be lodged “shortly”

ReNeuron confirmed it will “shortly” submit an investigational new drug application to the US Food and Drug Administration to kick off a clinical trial in the US in stroke patients.

Data from that study is expected at some point in the second half of 2019. After that, the company reckons it will need one more study in order to get global marketing approval of the therapy.

Shares were up 2.1% to 1.71p in early deals on Monday.

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Laboratory
Thu
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use